Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

The Effect of Different Deproteinizing Agents on the Clinical Success of Fissure Sealants in Primary Teeth

NCT07003958 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2024-08-05
Last updated
2025-06-04

Condition(s) studied

Fissure Sealant

Investigational drug(s) / intervention(s)

application of deproteinization agents

application of deproteinization agents: Since there is no in vivo study in the literature evaluating the clinical success of the use of hypochlorous acid for deproteinization in fissure sealants, our planned study is the first in this regard.

Study summary

Investigation of the effect of deproteinization agents on the clinical success of non-invasive fissure sealant application, which is a non-invasive method used to prevent caries formation or to stop the progression of initial caries lesions limited to enamel on tooth surfaces thought to be at high risk of caries.

Eligibility

Sex
ALL
Min age
4 Years
Max age
6 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Patients between the ages of 4-6 who do not have any systemic problems * Have a score of 3 and 4 on the Frankl Behavior Scale * Do not have a habit of clenching and/or grinding their teeth * Have lower second primary molars without caries * Have an indication for fissure sealant application Exclusion Criteria: * Teeth with fissure sealants * Teeth with developmental defects such as hypoplasia * Teeth with approximal or incipient caries lesions on one or both mandibular second primary molars

Primary outcome measure(s)

  • Modified Simonsen Criteria — Following the sealant application, controls will be made at 3,6, 12 and 24 months
    Modified Simonsen Criteria Score 0 Fissure sealant is completely in the mouth and there is no new caries. Score 1 Partial loss of fissure sealant, no new caries. Score 2 Partial loss of fissure sealant and new caries. Score 3 Complete loss of fissure sealant, no new caries. Score 4 Complete loss of fissure sealant and new caries.

Trial sites (1)

FacilityCityRegionStatus
Tokat Gaziosmanpaşa University, Tokat, 60030 Tokat Province Turkey (Türkiye) Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07003958 on ClinicalTrials.gov ↗ ← All trials in Turkey